Cannabis lowered some lipid risks but raised kidney concerns
Safety and Efficacy Assessment of Cannabis Plant Compared to Atorvastatin for Lipid Lowering in Diabetic and Obese Wistar Male Rats.
AI Summary
This small animal study compared cannabis plant extract with atorvastatin in 14 obese, diabetic male rats over 30 days. Both treatments improved some atherogenic indices, which estimate cardiovascular risk, but atorvastatin produced the stronger lipid-related effects. Cannabis extract modestly improved the overall lipid profile, while it did not change LDL cholesterol; the abstract does not establish that cannabis is an effective replacement for statins.
The safety findings were mixed. Liver enzymes rose with atorvastatin but remained virtually unchanged with cannabis extract, suggesting less apparent liver impact in this model. However, serum creatinine increased with cannabis treatment, indicating a potential renal safety concern. The researchers also cite possible neurological and addiction-related consequences, concluding that these issues limit the treatment’s applicability to humans and require further study.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.